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Summary Using CM-1 antibody directed against the human p53 protein, high levels of mutant p53 protein
expression were found in 12 out of 18 malignant choroidal melanomas. In contrast, we failed to observe
elevated p53 expression, indicating the absence of p53 mutation in seven choroidal naevi, a potentially
premalignant condition that can progress to form malignant melanoma. For two choroidal melanomas, we
demonstrated that high levels of p53 protein were accompanied by exon 7 mutations. The mutations were
found at codon 238, TGT-*TTT and codon 253, ACC-*AGC. These observations suggest that acquisition of
abnormalities of the p53 gene may be an important step in the development of malignant melanoma.
Choroidal melanoma is the commonest intraocular malig-
nancy in adults. It is classified on a histological basis into
spindle cell, epithelioid, and mixed cell types. Prognosis of the
disease is uncertain and metastasis, usually in the liver, can
occur up to 16 years after the apparently successful removal
of the eye (Willis, 1960; Egan et al., 1988). Apart from some
reports of melanomas developed from pre-existing naevi,
which are benign pigmented spots in the choroid (Yanoff &
Zimmerman, 1967), the aetiology of the disease is unclear.
One of the fundamental problems in the management of this
disease is the lack of understanding of the biological factors
that govern its behaviour. Unlike other tumours, including
cutaneous melanoma, little research has been carried out to
identify and analyse the role of oncogenes and tumour supp-
ressor genes in the development and prognosis of choroidal
melanoma.
Recent evidence suggests that mutation of the p53 suppres-
sor gene is one of the commonest abnormalities found in
human cancers (Levine et al., 1991; Caron de Fromental &
Soussi, 1992). This gene is located on the short arm of
chromosome 17 and encodes a 53 kDa nuclear protein that
appears to be involved in regulating the cell cycle. The
normal p53 product has been shown to act as a tumour
suppressor (Finlay et al., 1989; Baker et al., 1990a), but
various point mutations within the coding region of the gene
inactivate or alter this function (Eliyahu et al., 1988; 1989;
Finlay et al., 1989; Hinds et al., 1989; Baker et al., 1990a;
Diller et al., 1990; Mercer et al., 1990). Point mutations in
the p53 gene increase the stability of its protein product and
lead to an increase in the level of mutant protein present in
the cell (Finlay et al., 1988). This allows immunohis-
tochemical techniques to be used to screen for p53 mutations,
since the low levels of wild type protein normally present in
cells cannot be detected by this method (Cattoretti et al.,
1988; Van Den Berg et al., 1989; Bartek et al., 1990; Iggo et
al., 1990; Rodrigues et al., 1990; Gusterson et al., 1991). To
assess the role of p53 in the development and progression of
choroidal melanoma, we examined the level of p53 protein
and screened for the presence of mutation in the gene in
choroidal melanoma and choroidal naevi.
Materials and methods
Eighteen choroidal melanoma tissues (16 snap-frozen and
two paraffin embedded), seven paraffin embedded choroidal
naevi, five paraffin embedded highly pigmented eyes and two
snap-frozen normal eyes were used in this study. Six ftm
sections were prepared from these tissues prior to staining.
Snap-frozen tissues were stored at - 70°C and were not fixed
prior to the preparation of sections, while paraffin embedded
tissues were fixed with 10% formal saline.
Immunohistochemistry
Polyclonal rabbit anti-human p53 antibody designated CM-1,
and kindly donated by Dr D. Lane (CRC Unit Dundee
University) was used for immunostaining for p53 in the
tissues. This antibody was raised against the full length
human p53 and is specific for the human p53 protein (wild
and mutant types). The antibody was successfully detected by
alkaline phosphatase-antialkaline phosphatase (APAAP) tech-
nique (Cordell et al., 1984; Iggo et al., 1990). Briefly, sections
were incubated first with 10% bovine serum albumin (BSA)
in Tris-buffered saline (TBS) for 30 min, then with CM-1
anti-human p53 antibody at a dilution of 1:750 for 1 h. After
washing with TBS, sections were incubated with mouse-anti
rabbit immunoglobulin (DAKO Rabbit Ig) for 30 min, then
incubated with rabbit anti-mouse immunoglobulin (DAKO)
for 30 min, followed by mouse APAAP complex for a further
30min. The last three steps were repeated for 10 min each
before colour development with naphthol AS-BI phosphate
and freshly prepared new fuchsin. Known positive breast
carcinoma tissue was used as a positive control. Omission of
the primary antibody CM-1 from the staining was used as a
negative control. Sections with visual estimates of more than
10% of positive cells were considered positive.
Western analysis
Seventeen tissue samples (11 choroidal melanoma, three
choroidal naevi, one highly pigmented eye and two normal
control eyes) were examined by western blot analysis. Tissues
were lysed mechanically with a homogeniser in SDS gel
loading buffer (50 mM Tris.Cl pH.6.8, 100 mM dithiothreitol,
2% SDS, 0.1% bromophenol blue, 10% glycerol) and
incubated at 95°C for 10 min. Tissue lysate was heated to
95°C for 4 min immediately before being loaded onto a SDS-
polyacrylamide gel. After electrophoresis, proteins were
transferred to nitrocellulose membranes by electroblotting
and p53 protein was identified by an immunodetection
method described previously (Sambrook et al., 1989) using
CM-1 anti-human p53 antibody.
Polymerase chain reaction and direct sequencing ofp53 gene
Sections were lysed at 50°C overnight in 30 tlA of buffer
containing 75 mM NaCl, 25 mM EDTA, 0.1% Nonidet P-40,
and proteinase K at a concentration of 1 mg ml-', and then
boiled for 10 min at 100°C. Ten fil of each sample were then
used in 50 cycles of amplification by the polymerase chain
reaction (PCR) (Saiki et al., 1988). The PCR reaction mix-
ture (100 LIl) contained 50 mM KC1, 10 mM Tris-Cl, pH 8.3,
1.5 mM MgCl2, 0.01% (w/v) gelatin, 400tM dATP, dCTP,
dGTP, and dTTP, 25 pmole of each primer (a and b to
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Figure 1 Immunohistochemical analysis of p53 expression in choroidal melanoma: (a and b) Positively stained choroidal melanomas (magnification 850 x ); and (c) naevus showing no expression of mutant p53 protein (magnification 850 x ).902 K. TOBAL et al.
amplify exon 5; c and d to amplify exon 7; and e and f to
amplify exon 8) and two units of Taq DNA polymerase.
These exons were chosen because previous reports indicated
that they account for the majority of mutations in the p53
gene in other classes of human tumours (Nigro et al., 1989).
Primers used were (location is given between brackets):
(a) 5' ATCTGTTCACTTGTGCCCTG 3' (intron 4);
(b) 5' AACCAGCCCTGTCGTCTCTC 3' (intron 5);
(c) 5' GCTTGCCACAGGTCTCCCCAA 3' (intron 6);
(d) 5' AGGGGTCAGCGGCAAGCAGA 3' (intron 7);
(e) 5' GGACCTGATTTCCTTACTGC 3' (intron 7); and
(f) 5' CTTCTTTGGCTGGGGAGAGG 3' (intron 8).
Primers a, c and e have a biotin residue on their 5' end. This
was used to generate single stranded PCR products for direct
sequencing. To do that, PCR products were purified by
electrophoresis in 2% (w/v) low melting point agarose, and
single stranded products prepared using Dynabeads coated
with streptavidin. The PCR product was incubated with
Dynabeads coated with streptavidin for 30 min, which were
then washed with double distilled water. The DNA was
washed twice with 0.15 N NaOH to allow the separation of
the two strands of DNA, and the preparation of a single
stranded product attached to the beads. The final single
stranded product was sequenced using the dideoxy method as
previously described (Sanger et al., 1977).
Results
Using the CM-1 anti-human p53 antibody (Midgley et al.,
1992), elevated levels of p53 protein were detected in 12 out
of the 18 malignant choroidal melanomas. There was no
difference in the level of p53 staining detected between the
three histological classes of choroidal melanoma namely;
spindle cell, epithelioid, and mixed cell type (Figure 1, Table
I). Staining was confined to tumour cells; stroma and other
connective tissues were not stained-this indicated specific
staining for the p53 protein. Staining was predominantly
nuclear, but in some cases both nuclear and cytoplasmic
staining was observed. In contrast we failed to observe stain-
ing in seven choroidal naevi. We also failed to detect elevated
p53 protein, indicative of the presence of p53 mutation, in
five highly pigmented eyes, and two normal control eye
sections. In negative control experiments in which CM-1
antibody was omitted, tumour sections showed no staining.
Western analysis was used to examine the specificity of the
antibody used and to confirm over-expression of the p53
protein. As expected, high levels of p53 protein were detected
in lysates of tumour samples that exhibited staining in
immunohistochemical studies but not in lysates from
negatively stained tumours and naevi (Tables I and II). An
example of these studies is shown in Figure 2. To examine
whether the positive staining for p53 protein is related to the
presence of mutations in the gene, we carried out PCR
amplification and direct sequencing of exons 5, 7 and 8 of the
p53 gene from two tumours showing p53 over-expression and
one tumour that showed no staining (see Materials and
methods for details). These studies demonstrated the presence
of point mutations of codon 238 (TGT-*TTT, Cys-*Phe)
and codon 253 (ACC-*AGC, Thr-*Ser) in the two tumours
showing p53 over-expression. No mutation was observed in a
single tumour that failed to show over-expression. An exam-
ple of these analyses is shown in Figure 3.
Table II Comparative analysis of mutant p53 protein detection by
immunohistochemical and western blot techniques
p53 Western blot
Number Classif ication staining" analysis"
I epithelioid, melanoma positive positive
2 epithelioid, melanoma positive positive
3 spindle B, melanoma positive positive
4 spindle B, melanoma positive positive
5 spindle B, melanoma positive positive
6 spindle B, melanoma negative negative
7 spindle B, melanoma negative negative
8 mixed cell, melanoma positive positive
9 mixed cell, melanoma positive positive
10 mixed cell, melanoma negative negative
11 mixed cell, melanoma negative negative
12 choroidal naevus negative negative
13 choroidal naevus negative negative
14 choroidal naevus negative negative
15 highly pigmented eye negative negative
16 normal control eye negative negative
17 normal control eye negative negative
ap53 staining: There was no significant difference in the level ofp53
staining between the different tissues that stained positively with CM-1
antip53 antibody. bWestern blot analysis: All positive tissue lysates
showedastrong53 kDabandcorresponding tothep53protein. Negative
tissue lysates failed to show any band. (See Figure 2 for an example).
M M N
4- P53
Figure 2 Western blot analysis of the expression of p53 protein
in choroidal melanoma: Samples were from melanoma (M) and
naevus (N).
Discussion
Using an immunohistochemical technique, we have shown
that a high proportion of choroidal melanomas (12 out of
18) exhibit over-expression of p53 protein. The staining we
observed in these tissues was specific to the p53 protein, as
indicated by the positive and negative control samples, and
by western blot analysis which showed increased expression
of the p53 protein only in the lysates of tissues positively
Table I Immunodetection of mutant p53 protein in choroidal melanoma
No. examined No. No. examined No.
Classification by staining positive by Western blot positive
Melanoma 18 12 11 8
Naevi 7 0 3 0
Highly 5 0 1 0
pigmented eyes
Normal control 2 0 2 0
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Figure 3 p53 sequencing analysis. Exon 7 of the p53 gene was amplified by PCR and directly sequenced by the Sanger dideoxy
method. These results show the presence of point mutations in two malignant choroidal melanomas. (a) a TGT-TTT, Cys-Phe at
codon 238. (b) a ACC-AGC, Thr-Ser at codon 253. The arrow indicates the position of the mutation.
stained by the immunohistochemical technique. Staining was
predominantly nuclear, though in some cases both nuclear
and cytoplasmic staining was observed. Cytoplasmic staining
has been observed in other studies (Iggo et al., 1990; Dr. D.
Lane, personal communication). Iggo et al., 1990; suggested
that the cytoplasmic staining detected in small cell lung
tumours may be due to the presence of very high levels of
p53 protein and that this could be correlated with the poor
prognosis of the tumour. Sequence analysis which was car-
ried out on two positively and one negatively stained tissues
showed the presence of point mutations at exon seven of the
p53 gene in the two positively stained tissues, while the
negatively stained tissue tested showed no mutation in the
p53 gene. These point mutations occurred in a region of the
p53 gene that is highly conserved across several different
species (Soussi et al., 1990) and several human tumours have
been shown to have point mutations in these codons (Holl-
stein et al., 1991). When considered together, these observa-
tions show that a high proportion of choroidal melanomas
exhibit p53 staining and that this over-expression of the p53
protein correlates with the presence of point mutations in the
gene. Since premalignant choroidal naevi, some ofwhich may
progress into malignant melanomas (Yanoff & Zimmerman,
1967), failed to exhibit mutant p53 protein expression, it
appears that the acquisition of abnormalities in the p53 gene
is specifically associated with malignant tumours of the
choroid. It is therefore possible that p53 mutations could
play an important role in the progression of some naevi to
malignancy.
This hypothesis is supported by similar findings in other
human tumours, such as colorectal carcinomas, in which it
was found (Baker et al., 1990b) that both mutations and
allelic losses of chromosome 17 generally occur near the
transition from benign adenomas to malignant carcinomas.
We could not make a clear correlation between the presence
of p53 mutations and the prognosis of the disease, as all the
tissues used in this study were from recently enucleated eyes,
however, the examination of a large number of melanoma
tissues may paint a clearer picture regarding the relevance of
p53 mutations to the prognosis of the disease.
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